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Introduction
In spite of the efforts of the World Health Organization 
(WHO), the political commitment of its member states, 
scientific progress and the impressive technological ad-
vances of the vaccine industry, influenza continues to 
be a major public health problem, both because of its 
impact on the health of subjects at risk, such as the eld-
erly, and because of the economic burden that it places 
on society.
In the USA, influenza and its complications are respon-
sible for about 186,000 additional hospitalizations and 
44,000 deaths among the elderly (> 64 years) every 
year [1]. The risk of dying from influenza in the United 
States is 16 times higher among subjects over 84 years 
of age than among those aged from 65 to 69 years [2].
Among children under the age of 5 years, influenza is 
a frequent cause of medical examination and hospitali-
zation. In the USA, the incidence of emergency room 
admissions for influenza among children is estimated to 
have ranged from 6 to 27 per 1000 in the 2002-03 and 
2003-04 winter seasons [2]. The rate of hospitalization 
due to influenza is substantially similar to that of sub-
jects at risk, including those over 64 years of age [2]. 
As is well known, the following categories are at risk: 
pregnant women, subjects with pulmonary, cardiovascu-
lar, kidney, liver, hematological and metabolic diseases, 
immunodepressed patients, ecc.
Influenza vaccines are safe and reasonably efficacious; 
indeed, in most advanced countries, elderly people are 
regarded as a risk group for whom vaccination is a pri-
ority. Nevertheless, from 2005 to 2007, the efficacy of 
vaccinating such subjects was hotly debated, especially 
after a study by Jefferson et al. [3] that had been pub-
lished in the Lancet in 2005.
In order to make a substantial contribution to the is-
sue, Nichol et al. conducted a survey of 713,872 eld-
erly members of the general population in the United 
States from 1990 to 2000. They found that, during those 
10 seasons, influenza vaccination was associated with 
a significant reduction (27%) in the risk of hospitaliza-
tion and of death (48%) [4]. Previously (1995), Gross et 
al. [5] had carried out a meta-analysis of cohort studies, 
which had revealed a 50% reduction in hospitalizations 
and a 68% reduction in mortality. In other studies, con-
ducted in Liguria, vaccine efficacy in the elderly was 
estimated to be 57.11% (1999-2000 season) and 45.74% 
(2000-2001 season) [6-7].
However, it is well known that vaccines must be con-
tinually updated, and that when the “forecasted” viruses 
do not closely correspond to those actually in circula-
tion vaccination proves to be suboptimal; consequently, 
there is plenty of room for improvement.
Moreover, considering the risk of periodic pandemics, 
in recent years adjuvated vaccines have been developed 
and authorized for marketing in Europe. One of these is 
the virosomal adjuvated vaccine, which is now author-
ized for administration to all age-groups and is particu-
larly indicated for subjects at risk.
The present critical review of the scientific literature 
examines the characteristics of the virosomal adjuvated 
vaccine, the results yielded by controlled clinical stud-
ies and the pharmaceutical-economic implications, and 
makes an appraisal of the use of this product since 1997 
and of its future prospects.
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Summary
In spite of the efforts of the World Health Organization (WHO), 
influenza continues to be a major public health problem, both 
because of its impact on the health of subjects at risk, such as 
the elderly, and because of the economic burden that it places on 
society.
Adjuvants are agents which, when incorporated into vaccines, 
enhance the immunogenicity of their antigens. The need for ever 
more immunogenic and efficacious influenza vaccines has led to 
the development of innovative vaccines. One of these, the viro-
somal vaccine, has been on the market since 1997.
The results obtained through controlled clinical studies and wide-
spread application in the field suggest that the virosomal vaccine 
is not only an important tool for the prevention of seasonal influ-
enza but also a valid means of potentiating the effect of a pan-
demic influenza vaccine and, perhaps, of preparing multivalent 
or combined vaccines.
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Adjuvants
Adjuvants are agents which, when incorporated into 
vaccines, enhance the immunogenicity of their antigens. 
The first insights into this phenomenon are attributable 
to Gustave Ramon in 1925 [8]; however, it was Glenny 
who, the following year, discovered the adjuvating ef-
fect of aluminum salts [9]. The most recent vaccines are 
highly purified; this has almost totally eliminated the 
exotoxins, endotoxins, extraneous proteins, etc, which 
exerted an intrinsic adjuvating action on vaccines [10].
With regard to influenza, the first preparations, which 
were chemically purified, contained many egg proteins. 
Advances in the purification of this vaccine have made 
it possible to achieve greater tolerability. Nevertheless, 
the need for ever more immunogenic and efficacious 
influenza vaccines, especially for subjects at risk, has 
prompted the development of alternative vaccines; these 
are adjuvated not only with aluminum salts, but also 
with new preparations such as squalene and phospholip-
ids (virosomes) [11, 12].
Liposomes and virosomes
In 1974 Allison and Gregoriadis discovered the adjuvat-
ing role of liposomes [12]. In 1992 the first vaccine ad-
juvated with virosomes was proposed. This was a hepa-
titis A vaccine [13]. The mechanism of action was not 
well known at the time and was attributed to a depot 
effect involving the slow release of the antigen, and to 
the ability of the antigen and the vesicles to migrate to 
the regional lymph-nodes after injection.
Subsequently, virosomes were used in the preparation 
of influenza vaccines. Technically, the influenza viro-
somes are spheres of lipid vesicles with a mean diameter 
of 150 nm (Figs. 1, 2), from whose surface emerge spi-
cules of 10-15 nm. They are prepared by removing the 
surface glycoproteins of the influenza virus by means 
of detergents; these glycoproteins are then mixed with 
natural and synthetic phospholipids such as phosphati-
dylcholine and phosphatidylethanolamine [13].
Thus, the virosome presents as a vesicle delimited by a 
lipid monolayer which is very similar to that of the cell 
membrane. Structurally and functionally, the virosome 
is a reconstituted sheath of the influenza virus, bereft of 
genetic material.
Phosphatidylethanolamine is able to directly stimulate 
the B cells to produce antibodies against the antigens 
present on the virosome without inducing an antibody 
response against the phospholipids that make it up. The 
presence of the surface antigens of the influenza virus 
on the virosome then stimulates the phagocytosis of the 
presenting antigen cells, such as macrophages and den-
dritic cells.
Wilscht and McElhaney [14] have recently hypothesized 
that, as a result of the repetitive arrangement of the he-
magglutinin on their surface, virosomes interact very effi-
ciently with the immunoglobulin receptors of the B lym-
phocytes. Moreover, virosomes are thought to be avidly 
captured by the cells presenting the antigen, in particular 
the dendritic cells. The antigens present on the surface 
of the virosome, and those derived from its degradation, 
penetrate the MHC II (Major Histocompatibility Com-
plex II) class cells and activate the T-helper cells. In ad-
dition, through the fusion of the virosomes, the antigens 
inside the virosome enter into the cytosol, activating the 
MHC I (Major Histocompatibility Complex I) cells of 
innate immunity and the cytotoxic T lymphocytes. Thus, 
virosomes display the characteristics of an adjuvating 
system, are biodegradable, atoxic and do not induce the 
formation of antibodies against themselves [15].
Finally, virosomes appear to be a flexible platform that 
is particularly suited to the potentiation of prophylac-
tic, therapeutic and combined synthetic vaccines [16]. 
Indeed:
• their virus-like structure provides the B lymphocytes 
with a repetitive antigenic presentation and mimics 
the natural presentation of the antigen, which makes 
for a humoral response that is specific and of high 
quality [17, 18];
• the functional activity of fusion of the virosomes ac-
tivates the receptors, giving rise to a natural process 
of intracellular elaboration of the antigen and to acti-
vation of both humoral and cellular immunity;
Fig. 1. architectural structure of the virosomal adjuvated influenza vaccine on electron microscopy (electron microscopy Unit of the de-
partment of health sciences - dissaL – University of genoa).
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• the antigen is partially protected from extracellular 
degradation; this allows more prolonged stimulation 
of the immune system;
• virosomal vaccines seem to be particularly useful in 
children, the elderly (immuno-senescent) and immu-
nodepressed subjects.
To date, virosomal vaccines have been developed for 
hepatitis A and influenza; millions of doses have been 
administered and their safety and tolerability profile has 
proved to be very good.
Virosomal influenza vaccines: past, 
present and future
The first important experimental study of a virosome-
adjuvated vaccine in humans was conducted by Gluk et 
al. in 1994 [19]. The study compared a virosomal vac-
cine with an inactivated whole vaccine and a subunit 
vaccine, and showed that the virosomal vaccine was able 
to induce significantly higher antibody titers, serocon-
version and antibody responses to all three components 
contained in the vaccine (H1N1/Singapore 6/86, H3N2/
Beijing 353/89 and B/Yamagata 16/88) among the resi-
dents of a facility for elderly people.
Later, Conne et al. [20] conducted a double-blind study 
on geriatric patients. They found that, although both 
vaccines studied (virosomal and subunit, containing the 
strains A/Singapore 6/86, A/Beijing 32/92 and B/Pana-
ma 45/90) elicited significant increases in the geometric 
mean titer for the three viral strains, the virosomal vac-
cine induced an antibody response (4-fold increase in the 
titer) for the A viruses in a significantly higher number 
of recipients. With regard to the B virus, the percent-
age of subjects displaying protective titers (≥ 1/40) one 
month after vaccination was significantly higher among 
subjects who had received the virosomal vaccine. Fi-
nally, of those subjects who had had low antibody levels 
before vaccination (< 1/40), a statistically higher number 
displayed protective levels for both A viruses when they 
had received the adjuvated vaccine. The authors under-
lined the fact that 68.4% of the subjects vaccinated with 
the virosomal vaccine displayed protective antibody 
levels towards the three viruses, as against only 38% of 
those vaccinated with the subunit vaccine. 
In a study published in 2001, Pregliasco et al. [21] com-
pared a virosomal vaccine with a whole virus vaccine 
and a vaccine adjuvated with squalene (MF59). The 
results showed that both the virosomal vaccine and the 
squalene-adjuvated vaccine elicited greater antibody re-
sponses than the inactivated whole vaccine. 
Mensi et al. [22] studied the cell-mediated response in 
two groups of elderly subjects after vaccination with a vi-
rosomal vaccine and a whole vaccine. Innate immunity, 
which is of fundamental importance in defense against 
viral diseases, was analyzed by assaying interleukin 2 
(IL-2) and gamma interferon (IFNγ), while adaptive im-
munity (which leads to the production of antibodies, but 
which needs to be triggered by innate immunity) was an-
alyzed by assaying interleukin 4. The results of the study 
showed that the virosomal vaccine was able to activate 
both innate and adaptive immunity, the logical conse-
quence of which was an increase in specific antibody 
titers. The whole vaccine proved to be less efficacious in 
inducing the production of antibodies.
In the 2000/2001 season, experimentation involving 363 
subjects revealed an 80.6% level of protective efficacy 
of a virosomal vaccine in terms of a reduced incidence 
of flu-like illness [23].
Another comparative study of a virosomal vaccine and 
a vaccine adjuvated with MF59 (FLUAD) [24] showed 
that both vaccines stimulated the production of antibod-
ies to levels above the minimum thresholds of protection 
established by the ad hoc EMEA commission [25] for 
the three antigens contained in the vaccine and recom-
mended by the WHO for the 2002/2003 season. Moreo-
ver, it was seen that at least 90% of the subjects involved 
proved to be sero-protected 28 days after vaccination. 
The rates of sero-protection were comparable between 
the two vaccines and both vaccines displayed a very 
Fig. 2. mechanism of stimulation of a dendritic cell by virosomes. 
the virosome enters the cell and forms an endosome. from the 
endosome, the virosome is released into the cytosol; this is the 
site of the antigenic rearrangement that leads to presentation 
to the mhc ii cells (cd4+), which, following stimulation, produce 
lymphokines such as interleukin 2 and gamma interferon. the 
differently elaborated antigen is presented to the mhc i cells, 
stimulating innate immunity. the virosome binds to a toll-like 
recptor and this induces the production of pro-inflammatory 
lymphokines such as interleukin 1, 8, 12 and tnf-alpha.
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good safety profile. However, the virosomal vaccine 
was better tolerated: pain at the injection site, systemic 
reactions and the administration of drugs to treat adverse 
reactions were all significantly lower in the virosomal 
vaccine group.
In the 2002-03 season, Consonni et al. [26] studied 347 
elderly subjects who were vaccinated with either a vi-
rosomal vaccine alone (166 subjects) or the virosomal 
vaccine and a 23-valent pneumococcal vaccine (139 
subjects). A group of 69 unvaccinated subjects served 
as controls. All subjects were followed up with respect 
to clinical symptoms over the winter season. Flu-like 
symptoms were recorded in 6.6% of the subjects who 
had received the virosomal vaccine alone; among those 
who had received both vaccines, the incidence was 4.3%, 
while in the control subjects it was 17.3% (the difference 
from the two previous groups being highly significant). 
This study also confirmed the very good safety and tol-
erability profile of the virosomal vaccine.
In an open controlled clinical study conducted in the 
2002/2003 season on 840 elderly subjects, a split vac-
cine, a vaccine adjuvated with MF-59 and a virosomal 
vaccine were administered to three groups of volun-
teers [27]. The three preparations displayed high im-
munogenicity and an acceptable tolerability. Local side-
effects were more frequent when the MF-59-adjuvated 
vaccine was administered.
In 2005 de Bruijn et al. [28] evaluated three clinical tri-
als involving virosomal vaccines. In one of the trials, 
926 adults (18-60 years) received either the virosomal 
preparation or a conventional subunit vaccine. In an-
other trial, a virosomal vaccine and a split vaccine were 
compared in participants (87) over 60 years of age. The 
third trial aimed to check immunogenicity after one year 
in adults (42 subjects, 18-60 years) revaccinated with a 
virosomal vaccine. Having analyzed these studies, the 
authors concluded that: 
• the virosomal vaccine was safe and efficacious in all 
subjects studied, including those at risk of influenza-
related complications; 
• the virosomal vaccine was better tolerated than the 
subunit vaccine at the local level; 
• for the A-H3N2 strain, the virosomal vaccine stimu-
lated the production of antibodies, the levels of which 
remained high over time, regardless of the age and 
state of health of the recipients.
Other studies have documented the good tolerability 
and immunogenicity of virosomal vaccines in children, 
adults and subjects at risk. This is important in that in-
fluenza in children can have particularly serious conse-
quences [29-34]; moreover, it has been hypothesized that 
in some categories of subjects at risk, such as asthmatics, 
the vaccination might facilitate the acute recurrence of 
the allergic disease. In 2004 Kanra et al. [35] published 
a study carried out on 453 children aged between 6 and 
71 months, in which very good immunogenicity was ob-
served. More recently (2010), Esposito et al. [36] stud-
ied the immune response to and tolerability of a double 
dose of virosomal vaccine (0.5 ml) in children aged less 
than one year. They found that there was no significant 
increase in side-effects in comparison with the standard 
dose (0.25 ml), while both the short- and long-term anti-
body response increased significantly.
Salleras et al. [37] used both clinical and laboratory 
methods (Real Time Polymerase Chain Reaction, RT-
PCR) to evaluate the clinical efficacy of a virosomal 
vaccine in children aged 3-14 years in September-Octo-
ber 2004. The study revealed a vaccine efficacy of 75% 
in preventing cases of influenza-like illness (ILI) and of 
88% in preventing laboratory-confirmed cases.
In a study published in 2000 [38] involving children and 
adolescents with cystic fibrosis, administration of a vi-
rosomal vaccine proved to be safe and to have a strong 
immunogenic effect. In children (3-9 years old) with 
asthma, vaccinated in the 2005-2006 winter season [39], 
very good tolerability and immunogenicity were re-
corded. Nevertheless, in children without antibodies be-
fore vaccination, protection declined markedly after six 
months; this underscores the need for a booster dose one 
month after the first dose, and the advisability of subse-
quent annual revaccination.
In asthmatic children, Esposito et al. [40] confirmed the 
very good tolerability of the vaccine both in children 
with asthma and allergy to eggs (mean age 6.03 years) 
and in those with persistent asthma but without allergy 
to eggs (mean age 6.34 years). In addition, the vaccine 
has proved to be safe, well tolerated and endowed with 
good immunogenic power both in children [41-43] and 
in HIV-positive adults [44].
The vaccine is therefore well tolerated by subjects with 
conditions that are at risk, including those with scleroder-
ma, as demonstrated by Setti et al. [45] in subjects over 
the age of 18 years who had suffered from the disease for 
at least six months. Finally, Gaeta et al. [46] also demon-
strated the immunogenicity and safety of the vaccine in 
subjects with decompensated cirrhosis of the liver.
Economic studies
The economic benefits attributable to virosomal influ-
enza vaccines have mainly been studied with regard 
to children [47, 48]. However, a study conducted by 
Gasparini et al. [49] involved elderly non-institutional-
ized subjects.
In the above-mentioned study conducted by Salleras 
et al. [37], comparison between vaccinated and unvac-
cinated children revealed the advantages of vaccina-
tion: a 20% reduction in the consumption of antibiotics, 
a 46.9% reduction in absences from school, and 28% 
less absenteeism from work on the part of other fam-
ily members. In similar studies carried out by Principi 
et al. [50, 51] on children between 2 and 5 years of age 
who had received two doses of virosomal vaccine, the 
consumption of antibiotics fell by 32%, school absences 
by 48% and maternal absenteeism from work by 33%. 
Marchetti [52] et al. used a Markovian simulation mod-
el to assess the cost-effectiveness of a virosomal vac-
cine. They found that the vaccine was cost-saving from 
the point of view of society and cost-effective (from € 
10,000 to € 13,333 per year of life gained in good health 
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[QUALY]) from the standpoint of the third-party payer 
(National Health Service [NHS]).
The study conducted on elderly subjects by Gasparini et 
al. [49] was a cost/benefit analysis from the standpoint 
of the NHS as the third-party payer. The virosomal vac-
cine was compared with the conventional vaccine (sub-
unit or split). The simulation of the study enabled the 
authors to conclude that the virosomal vaccine yielded 
a saving of € 124 (purchasing power as of 2002) versus 
€ 108 yielded by the conventional vaccine. Moreover, 
sensitivity analysis revealed that, even when the efficacy 
of the virosomal vaccine was considered to be 46%, it 
was still more advantageous than that subunit or split 
vaccine.
Conclusions and prospects
The experiences quoted indicate that virosomal vaccines 
hold out good hopes of overcoming some critical aspects 
of vaccination for the elderly, one of which is immuno-
senescence. This type of vaccine is very well tolerated 
owing to the characteristics of the virosomes, which are 
very similar to the composition of the cell membrane.
The mechanism of action of a good adjuvant must al-
ways be suitably balanced. Indeed, in anti-viral vaccines 
the adjuvant must first of all stimulate innate immunity 
and then the MHC I class cells, which are essential in 
killing infected cells and coordinating their elimina-
tion. These MHC I class cells produce pro-inflamma-
tory lymphokines and chemokines, which recruit other 
cells that play a role in the immune response [53]. These 
lymphokines and cells are also responsible for the side-
effects of vaccination, which are usually evident at the 
local level, such as pain, redness and swelling. However, 
the adjuvant must also activate the regulatory cells in an 
appropriate manner, so that they can correctly temper 
the immune response, thereby limiting the time and in-
tensity of the immune reaction. Moreover, activation of 
the MHC I cells conditions the adaptive response and 
the consequent production of antibodies in such a way as 
to ensure a consolidated, long-standing (e.g. 12 months) 
response.
Virosomal influenza vaccines have been on the European 
market for more than 10 years, and more than 41 million 
doses have been sold. Post-marketing surveillance has 
shown that they have an excellent safety and tolerability 
profile; this is also due to their purity, the absence of 
formaldehyde and thyomerosal, their very low content 
of egg protein and their biocompatibility.
The production of antibodies, which, in the final anal-
ysis, expresses the activation of adaptive immunity, is 
better elicited by virosomal vaccines than by whole or 
subunit or split vaccines, particularly with regard to the 
viruses A/H3N2 and B. Indeed, conventional vaccines 
have often proved poorly immunogenic against this lat-
ter type of virus.
In conclusion, within the wide range of influenza vac-
cines available, virosomal vaccines display very good 
tolerability and high immunogenicity in subjects of all 
age-groups as well as in subjects with pathologies that 
constitute risk factors for post-influenza complications, 
such as asthmatics, those with scleroderma and HIV-
positive subjects. This means that virosomal vaccines 
have great flexibility and are particularly useful in sea-
sonal immunization programs.
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